Sanofi is to take on Boehringer Ingelheim's consumer health division ... and is a good fit with its existing business in terms of products and geographies, giving it much increased market share ...

The One Medicine Platform replaces 20+ legacy platforms—unifying medicinal development processes & data sources into a ...

Two years after first announcing the partnership, Boehringer Ingelheim and software firm Veeva Systems have launched ...

Privately-held Swedish firm Salipro Biotech AB, a specialist in the stabilization of challenging drug targets, today ...

Germany’s Boehringer Ingelheim has launched the One Medicine Platform, a new system designed to streamline drug development, ...

"With this new system, Boehringer Ingelheim is expected to resolve data challenges and latencies and speed up the go-to-market of its products. Thanks to the close collaboration across our teams ...

Salipro Biotech has signed a research and license agreement with Boehringer Ingelheim to accelerate the development of ...

A big dampener to Lupin’s plans would be the potential imposition of tariff on pharma products by the Trump government.

The collaboration combines Salipro Biotech’s unique expertise and its Salipro® platform technology to stabilise challenging drug targets from Boehringer Ingelheim’s drug discovery programs to enable ...

Cognizant (Nasdaq: CTSH) and Boehringer Ingelheim announced today the go-live of an end-to-end technology platform powered by ...

Boehringer Ingelheim is a biopharmaceutical company active in both ... Veeva Forward-looking Statements This release contains forward-looking statements regarding Veeva's products and services and the ...

Boehringer Ingelheim and Veeva Systems have announced the launch of Boehringer’s One Medicine Platform, powered by the successful implementation of Veeva Development Cloud. They ...